167 related articles for article (PubMed ID: 17515695)
21. They are from the government and they really are here to help you.
Woosley RL
J Clin Pharmacol; 2008 Feb; 48(2):142-3. PubMed ID: 18199889
[No Abstract] [Full Text] [Related]
22. Communicating with the FDA: the "third rail" of a new model for drug development.
Stanski DR; Orloff JJ
J Clin Pharmacol; 2008 Feb; 48(2):144-5. PubMed ID: 18199890
[No Abstract] [Full Text] [Related]
23. Piercing the veil of corporate secrecy about clinical trials.
Lemmens T
Hastings Cent Rep; 2004; 34(5):14-8. PubMed ID: 15553393
[No Abstract] [Full Text] [Related]
24. Performing trials in children with rheumatic diseases: comment on the editorial by Lehman.
Ruperto N; Martini A; Lovell DJ; Giannini EH; ;
Arthritis Rheum; 2008 Apr; 58(4):1201-2; author reply 1203. PubMed ID: 18383366
[No Abstract] [Full Text] [Related]
25. Balancing safety, effectiveness, and public desire: the FDA and cancer.
Conti R
Issue Brief (Commonw Fund); 2003 Apr; (615):1-6. PubMed ID: 12693391
[No Abstract] [Full Text] [Related]
26. Trouble at the office.
Allison M
Nat Biotechnol; 2008 Sep; 26(9):967-9. PubMed ID: 18779797
[No Abstract] [Full Text] [Related]
27. Moment of reckoning.
Wadman M
Nature; 2007 Apr; 446(7138):844-5. PubMed ID: 17443154
[No Abstract] [Full Text] [Related]
28. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.
Davit BM; Nwakama PE; Buehler GJ; Conner DP; Haidar SH; Patel DT; Yang Y; Yu LX; Woodcock J
Ann Pharmacother; 2009 Oct; 43(10):1583-97. PubMed ID: 19776300
[TBL] [Abstract][Full Text] [Related]
29. Availability of comparative trials for the assessment of new medicines in the European Union at the moment of market authorization.
van Luijn JC; Gribnau FW; Leufkens HG
Br J Clin Pharmacol; 2007 Feb; 63(2):159-62. PubMed ID: 17166187
[TBL] [Abstract][Full Text] [Related]
30. Plan B OTC.
Med Lett Drugs Ther; 2006 Sep; 48(1243):75. PubMed ID: 16977288
[No Abstract] [Full Text] [Related]
31. The scope and requirements related to preclinical and clinical studies of a new medicinal product, including biotechnological and biosimilar products.
Brodniewicz-Proba T
Acta Pol Pharm; 2008; 65(6):641-5. PubMed ID: 19172845
[TBL] [Abstract][Full Text] [Related]
32. Earlier drug tests on people could be unsafe, critics warn.
Wadman M
Nat Med; 2006 Feb; 12(2):153. PubMed ID: 16462779
[No Abstract] [Full Text] [Related]
33. [Consequences of the 12th AMG amendment on the conduct of non-commercial clinical trials].
Rossion I
Urologe A; 2005 Dec; 44(12):1444-8. PubMed ID: 16283155
[TBL] [Abstract][Full Text] [Related]
34. [Off-label drug prescriptions].
Ilku L; Vizi J
Psychiatr Hung; 2007; 22(1):89-94. PubMed ID: 17642123
[No Abstract] [Full Text] [Related]
35. Clinical trial registration.
Zarin DA
N Engl J Med; 2005 Apr; 352(15):1611. PubMed ID: 15829551
[No Abstract] [Full Text] [Related]
36. Pediatric medicine. Europe follows U.S. in testing drugs for children.
Bosch X
Science; 2005 Sep; 309(5742):1799. PubMed ID: 16166486
[No Abstract] [Full Text] [Related]
37. Japan's conditional early approval program for innovative cancer drugs: Comparison of the regulatory processes with the US FDA and the EMA.
Murayama A; Ueda M; Shrestha S; Tanimoto T; Ozaki A
Cancer Cell; 2021 Sep; 39(9):1165-1166. PubMed ID: 34358449
[No Abstract] [Full Text] [Related]
38. Regulations and procedures for new drug evaluation and approval in China.
Yin H
Hum Gene Ther; 2006 Oct; 17(10):970-4. PubMed ID: 16958562
[No Abstract] [Full Text] [Related]
39. Cancer nanotherapeutics in clinical trials.
Lytton-Jean AK; Kauffman KJ; Kaczmarek JC; Langer R
Cancer Treat Res; 2015; 166():293-322. PubMed ID: 25895874
[TBL] [Abstract][Full Text] [Related]
40. Legislation would put drugs and other therapies to a useful test.
Carroll J
Manag Care; 2008 May; 17(5):12-3. PubMed ID: 18567462
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
